ENDEAVOR
to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure With Left Ventricular Ejection Fraction > 40%
- Stadium
- klaar
- Middel
- AZD4831
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 22 september 2022
- Last Patient In
- 31 maart 2023
- Last Patient Last Visit
- 31 maart 2024
Studiedirecteur
dr. S. van Wijk
Cardioloog
Contact Kantoor
